BPC-157s angiogenic effect addresses this root problem directly, which is why it has become the go-to recovery peptide in elite training circles and physiotherapy clinics that operate within the compounding pharmacy framework
#Alzheimers #Neurology #ClinicalTrials #Biotech #HealthcareInnovation #Phase2 #Neurodegeneration #NeuroSense #PrecisionMedicine To view or add a comment, sign in Were thrilled to share that our review article, SIRT3-mediated mitochondrial reprogramming: emerging therapeutic paradigms in peripheral neuropathy and neuropathic pain, has been published In Press in the prestigious Free Radical Biology and Medicine journal
The research shows potential for peptides to modulate the immune response driving MS, promote tissue repair including remyelination, and reduce neuroinflammation
It should not be presented as an authorised health claim
One daily draw
Edison P, Femminella GD, Ritchie C et al (2025) Liraglutide in mild to moderate Alzheimers disease: a phase 2b clinical trial
